Gemphire Therapeutics Inc. (GEMP) Reaches $7.14 After 6.00% Down Move; Morgan Stanley Has Upped Innerworkings (INWK) Position

March 14, 2018 - By Peter Erickson

The stock of Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a huge mover today! The stock decreased 4.67% or $0.35 during the last trading session, reaching $7.14. About 74,789 shares traded. Gemphire Therapeutics Inc. (NASDAQ:GEMP) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.The move comes after 7 months negative chart setup for the $98.36 million company. It was reported on Mar, 14 by We have $6.71 PT which if reached, will make NASDAQ:GEMP worth $5.90M less.

Morgan Stanley increased Innerworkings Inc (INWK) stake by 128.05% reported in 2017Q3 SEC filing. Morgan Stanley acquired 97,556 shares as Innerworkings Inc (INWK)’s stock rose 12.55%. The Morgan Stanley holds 173,741 shares with $1.95M value, up from 76,185 last quarter. Innerworkings Inc now has $494.14M valuation. It closed at $9.13 lastly. It is up 36.17% since March 14, 2017 and is uptrending. It has outperformed by 19.47% the S&P500.

Investors sentiment increased to 1.64 in Q3 2017. Its up 0.71, from 0.93 in 2017Q2. It improved, as 17 investors sold INWK shares while 39 reduced holdings. 13 funds opened positions while 39 raised stakes. 42.69 million shares or 2.29% more from 41.73 million shares in 2017Q2 were reported. Bnp Paribas Arbitrage Sa has 0% invested in InnerWorkings, Inc. (NASDAQ:INWK) for 5,427 shares. Ami Asset Management holds 1.22 million shares or 0.97% of its portfolio. Federated Pa accumulated 0% or 40 shares. Citadel Advsrs Ltd accumulated 21,276 shares. Bancorporation Of America Corp De reported 526,087 shares. Pnc Grp accumulated 12,635 shares. Indexiq Advisors Ltd Liability Corporation invested in 87,022 shares. Riverbridge Partners Limited Liability holds 0.69% of its portfolio in InnerWorkings, Inc. (NASDAQ:INWK) for 3.13M shares. Commercial Bank Of Mellon, New York-based fund reported 196,258 shares. 3.38M are held by Blackrock. 47,052 were accumulated by Pdt Prns Ltd Liability Corp. Greenleaf Tru has 0% invested in InnerWorkings, Inc. (NASDAQ:INWK) for 2,450 shares. Clarivest Asset Mgmt Ltd Co invested 0.01% of its portfolio in InnerWorkings, Inc. (NASDAQ:INWK). California State Teachers Retirement owns 72,173 shares or 0% of their US portfolio. Moreover, Campbell & Comm Adviser Ltd Liability Company has 0.19% invested in InnerWorkings, Inc. (NASDAQ:INWK).

Morgan Stanley decreased Wisdomtree Tr (HEDJ) stake by 1.94 million shares to 5.37M valued at $347.30M in 2017Q3. It also reduced Consolidated Edison Inc (NYSE:ED) stake by 797,346 shares and now owns 1.70 million shares. Rayonier Advanced Matls Inc (NYSE:RYAM) was reduced too.

Among 5 analysts covering Innerworkings (NASDAQ:INWK), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Innerworkings had 6 analyst reports since August 7, 2015 according to SRatingsIntel. Barrington Research maintained the shares of INWK in report on Monday, February 27 with “Outperform” rating. The stock of InnerWorkings, Inc. (NASDAQ:INWK) earned “Buy” rating by Wunderlich on Thursday, June 29.

Analysts await Gemphire Therapeutics Inc. (NASDAQ:GEMP) to report earnings on March, 21. They expect $-0.72 earnings per share, up 7.69% or $0.06 from last year’s $-0.78 per share. After $-0.82 actual earnings per share reported by Gemphire Therapeutics Inc. for the previous quarter, Wall Street now forecasts -12.20% EPS growth.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis . The company has market cap of $98.36 million. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News